Clinical Trials in Boston

Showing 2481-2500 of 8,503 trials

AAVCAGsCD59 for the Treatment of Wet AMD

NCT03585556

Patients with treatment naive wet AMD will receive an intravitreal anti-VEGF injection at Day 0 followed by an intravitreal injection of AAVCAGsCD59 at Day 7. Patients will be followed monthly through Month 12 and receive an intravitreal anti-VEGF injection as needed based on an increase in central subfoveal thickness (CST) of \>50 micrometers on OCT from Day 0, new subretinal hemorrhage on clinical exam, and/or loss of 10 or more ETDRS letters from the previous month exam.

Wet Age-related Macular Degeneration

Janssen Research & Development, LLC25 participantsStarted Sep 2018

Boston, Massachusetts, United States • Worcester, Massachusetts, United States

COMPLETEDPhase 3< 1 mile

Clinical Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Subjects

NCT03153137

The primary objective is to assess the effect of macitentan 10 mg as compared to placebo on exercise capacity through cardiopulmonary exercise testing.

Congenital Heart Disease

Actelion142 participantsStarted Aug 2017

Birmingham, Alabama, United States • Los Angeles, California, United States • Boston, Massachusetts, United States +29 more locations

AAVCAGsCD59 for the Treatment of Wet AMD

Clinical Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Subjects

Find Trials by Condition in Boston

Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure

A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease

Early Intervention in High Risk CCUS

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA

Safety and Efficacy of the SurVeil™ Drug-Coated Balloon

Early Feasibility Study of the MyoRegulator® for Treatment of ALS

A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events

Pharmacological Countermeasures for High Altitude

Optimal Post Tpa-Iv Monitoring in Ischemic Stroke

A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)

A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment

Noninvasive Monitoring of Uterine Activity and Fetal Heart Rate

Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab

Outcome of Patients with Severe Functional TR According to Medical, Transcatheter or Surgical Treatment

Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)

Antibiotic Prophylaxis Before Shock Wave Lithotripsy

Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female Subjects